Navigation Links
Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
Date:5/10/2011

e (CHF) and new onset CHF have been reported with TNF blockers.  Certolizumab pegol has not been formally studied in patients with CHF.  Exercise caution when using certolizumab pegol in patients who have heart failure and monitor them carefully.

Hypersensitivity

Symptoms compatible with hypersensitivity reactions, including angioedema, dyspnea, hypotension, rash, serum sickness, and urticaria, have been reported rarely following certolizumab pegol administration.  If such reactions occur, discontinue further administration of certolizumab pegol and institute appropriate therapy.

Hepatitis B Reactivation

Use of TNF blockers, including certolizumab pegol, may increase the risk of reactivation of hepatitis B virus (HBV) in patients who are chronic carriers of this virus. Some cases have been fatal.  Evaluate patients at risk for HBV infection for prior evidence of HBV infection before initiating certolizumab pegol therapy.  Exercise caution in prescribing certolizumab pegol for patients identified as carriers of HBV, with careful evaluation and monitoring prior to and during treatment.  In patients who develop HBV reactivation, discontinue certolizumab pegol and initiate effective anti-viral therapy with appropriate supportive treatment.

Neurologic Reactions

Use of TNF blockers, including CIMZIA, has been associated with rare cases of new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disease, including multiple sclerosis, and with peripheral demyelinating disease, including Guillain-Barre syndrome. Rare cases of neurological disorders, including seizure disorder, optic neuritis, and peripheral neuropathy have been reported in patients treated with CIMZIA. Exercise caution in considering the use of CIMZIA in patients with these disorders.

Hematologic Reac
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA)
2. Rapid and Long-term Clinical Responses Observed in Rheumatoid Arthritis Patients Taking Cimzia® (certolizumab pegol), According to Data Being Highlighted During ACR Meeting
3. UCB Presents Growing Body of Long-term Efficacy Data at ACG 2010 Meeting to Further Support Treatment with Cimzia® (certolizumab pegol) in Multiple Patient Populations with Moderate to Severe Crohns Disease
4. Long-Term Data on Cimzia® (certolizumab pegol) for Moderate to Severe Crohns Disease to be Highlighted at ACG Meeting
5. New Data Show CIMZIA(R) (certolizumab pegol) Provides Sustained and Significant Symptom Improvement in Moderate to Severe Crohns Patients
6. CIMZIA(R) (Certolizumab Pegol) Provides Rapid and Sustained Relief from Signs and Symptoms of Rheumatoid Arthritis for Two Years
7. CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohns Disease Patients
8. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
9. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
10. New Subanalyses of the RE-LY Trial Showed Pradaxa Reduced Stroke Risk in Patients With Varying CHA2DS2-VASc Scores and Types of Non-Valvular Atrial Fibrillation
11. Prolia® (denosumab) Open-Label Extension Trial Showed Continued Increase in Bone Mineral Density Over Five Years of Treatment With Similar Safety Profile Observed in Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 Research and Markets  has ... Pralmorelin" report to their offering. Global ... data on Pralmorelin globally and regionally ( Europe ... , Latin America etc.). It ... This report focuses on three primary areas; manufacture methods ...
(Date:8/20/2014)... 2014   Ventana Medical Systems, Inc.  (Ventana), ... that its VENTANA System for Primary Diagnosis 1 ... Union for routine pathology, including primary diagnosis with ... Virtuoso software coupled with either the VENTANA iScan ... provides automated digital slide creation, case management and ...
(Date:8/20/2014)... ANN ARBOR, Mich. and ... a non-profit corporation established to bring cutting-edge next-generation ... trials to cancer patients, today announced a collaboration ... molecular capabilities to characterize patient tissue samples from ... be sensitive or resistant to TESARO,s TSR-011.  This may ...
Breaking Medicine Technology:Global Market Report of Pralmorelin 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 2Full digitization of the anatomic pathology lab is here with the VENTANA System for Primary Diagnosis 3Paradigm Announces Molecular Profiling Collaboration with TESARO, Inc. 2
... Corp., formerly known as InstaCare Corp., (OTCQB: ISCRD), a ... the chronically ill, a leading fulfillment provider of direct ... revolutionary cell phone centric e -health products and ... Dividend will be Ex-Dividend to all shareholders of record ...
... ENDP ) today announced that David Holveck, president ... Morgan 30th Annual Healthcare Conference on Monday, January 9, 2012 ... the Westin St. Francis in San Francisco, Calif. ... be available on the company,s website at http://www.endo.com/ .  ...
Cached Medicine Technology:Decision Diagnostic Corp. Clarifies 10% Stock Dividend, Announces Patent Enforcement Strategy 2
(Date:8/21/2014)... 21, 2014 Only 20 percent of healthcare ... Affordable Care Act according to a new report . ... responding to a request from Smart Data pioneer ... lead providers to violate privacy laws in many states. , ... many hospitals and clinics are failing to do so in ...
(Date:8/21/2014)... 21, 2014 Inc. magazine ranked Centurion ... 500|5000, an exclusive ranking of the nation's fastest-growing private ... the most important segment of the economy—America’s independent entrepreneurs. ... LinkedIn, Zillow, and many other well-known names gained early ... is proud to have been named to the Inc. ...
(Date:8/21/2014)... Houston, TX (PRWEB) August 21, 2014 Sometimes you ... destiny. , In his new book “From Zero to a Hundred: ... police officer, shares his story of surviving a broken family, a ... “Adversity brings affirmation of who you were created to be,” Roy ... zero,’ which is why I know my purpose today of helping ...
(Date:8/21/2014)... CQIIP, Continuous Quality Immunization Improvement ... Control and Prevention and the Department of Defense. ... the immunization standards and are administered in accordance ... on Immunizations. , ACC chose to adopt the ... place to protect patients, improve efficiency, and increase ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 ... aging interventions and addressing the challenges of ... concept, OncoFinder, for signalome-wide pathway analysis. ... robust cross-platform analysis of gene expression data ... research, published in the journal Frontiers in ...
Breaking Medicine News(10 mins):Health News:Report: Only 20 Percent of Healthcare Providers Meet ACA Requirement 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 2Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 3Health News:Centurion Service Group Named to Inc. Magazine's List of the Nation's Fastest-Growing Private Companies 4Health News:Zero to a Hundred: True Story of Escaping Death to Meet Life 2Health News:ACC Health Raises the Bar Again by Completing the CQIIP Certification Program 2Health News:OncoFinder, a new algorithm for minimizing errors in high-throughput transcriptome analysis 2
... JUPITER, FL, May 28, 2009 Current tests to identify specific ... diseases (such as mad cow) in animals and humans, can ... results a time-lag that may put human populations at ... Research Institute,s Florida campus have developed a new method that ...
... Inc. (NYSE: DVA ) announced today ... the Company,s Board of Directors. (Logo: ... former President of American Express International, Japan, Asia-Pacific, ... the Consumer Card business across 12 countries, heading ...
... Annoying seasonal allergies is now a year round threat. ... to nest in the home. Indoor air pollution is ... chemicals, synthetic materials and impurities. To expel these year ... to home ventilation and eliminates allergens.The EZ Breathe system ...
... The best respiratory protection is useless if it ... series, Draeger dedicated special attention to ensuring that the ... comfort of the wearer was maximized. While offering extremely ... been compromised. (Photo: http://www.newscom.com/cgi-bin/prnh/20090528/NE24067 ...
... Darwin National,Assurance Company, a member company of Allied ... ), today announced that Becky Cox has been ... Ms. Cox will,be responsible for the continued development ... Fred Bautista, Vice,President, Business Development, Healthcare. , ...
... of overdose, and potential liver damage, is still too ... -- One month after mandating stricter warning labels about ... U.S. regulators are contemplating even tougher standards. , Advisers ... late next month to review a new agency report ...
Cached Medicine News:Health News:Scripps Florida scientists devise accelerated method to determine infectious prion strains 2Health News:Scripps Florida scientists devise accelerated method to determine infectious prion strains 3Health News:Pamela M. Arway Joins DaVita Board of Directors 2Health News:EZ Breathe(R) Home Ventilation System Expels Allergens, Moisture and Smells 2Health News:Comfort Matters - The new Draeger Series of Filtering Facepiece Respirators Demonstrate Exceptional Wearer Comfort 2Health News:Darwin Appoints Becky Cox Vice President, Business Development, Healthcare 2Health News:Darwin Appoints Becky Cox Vice President, Business Development, Healthcare 3Health News:FDA Report Urges Tougher Acetaminophen Warning 2
... Solution is the ... povidone-iodine. It is a ... kills gram-positive and gram-negative ... organisms), as well as ...
... Aplicare's disposable 1-ounce pouches are designed for ... waste. They are used in nursing homes, ... rooms and many other hospital departments. This ... is a mild antiseptic, germicidal and cleansing ...
... Aplicare's Iodine Scrub is a gentle ... formulated to prevent dryness. Povidone Iodine is ... gram-negative and gram-positive bacteria, fungi, viruses, protozoa ... lather; the first step in patient pre-operative ...
... Iodine Scrub is a gentle and effective ... prevent dryness. Povidone Iodine is known to ... gram-positive bacteria, fungi, viruses, protozoa and yeasts. ... first step in patient pre-operative prepping, as ...
Medicine Products: